This study is testing a new medicine called adagrasib for people with a specific lung cancer mutation called KRAS G12C. The study has two parts:

• Phase 2: Tests adagrasib alone or with another medicine called pembrolizumab in people with advanced non-small cell lung cancer (NSCLC). NSCLC means the cancer has spread and is not just in one place.
• Phase 3: Compares adagrasib with pembrolizumab against just pembrolizumab in people with more severe cases of NSCLC.

Both medicines work by trying to stop cancer cells from growing. Pembrolizumab helps your immune system fight cancer, while adagrasib targets the KRAS G12C mutation to stop cancer growth directly.

• Key Points to Consider:
• Participants must have a specific type of lung cancer with the KRAS G12C mutation.
• You cannot join if you have had certain treatments before or have certain brain conditions.
• Discuss possible risks and benefits with your doctor before joining.

Joining the study might involve regular doctor visits and treatments. Make sure to ask the study team any questions you have about what to expect.